UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

17 Exploring the future of dermatology at AAD 2023

Read More Share:

Mar

16 You Speak, We Listen: How Community Voices Drive Our Work in HS

Read More Share:

Mar

16 UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

Read More Share:

Mar

15 Building a Community of Trust in Epilepsy & Rare Syndromes

Read More Share:

Feb

23 Voices on Value: Building a Sustainable Healthcare System for a Healthier Tomorrow – The Second Annual U.S. Sustainable Access and Pricing Transparency Report

Read More Share:

Feb

17 Patient-First, Patient-Focused: Our Purpose and Promise

Read More Share:

Feb

07 Benjamin Jessie and Kurt Hughes Use Combined 50+ Years in Industry to Create New Experiences and Forums for Colleagues

Read More Share:

Jan

20 Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Read More Share:

Jan

18 Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Read More Share:

Jan

06 UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Read More Share:

Categories

Archives

Mar

17

Exploring the future of dermatology at AAD 2023

Mar

16

You Speak, We Listen: How Community Voices Drive Our Work in HS

Mar

16

UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

Mar

15

Building a Community of Trust in Epilepsy & Rare Syndromes

Feb

23

Voices on Value: Building a Sustainable Healthcare System for a Healthier Tomorrow – The Second Annual U.S. Sustainable Access and Pricing Transparency Report

Feb

17

Patient-First, Patient-Focused: Our Purpose and Promise

Feb

07

Benjamin Jessie and Kurt Hughes Use Combined 50+ Years in Industry to Create New Experiences and Forums for Colleagues

Jan

20

Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Jan

18

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Mar

17

Exploring the future of dermatology at AAD 2023

Mar

16

You Speak, We Listen: How Community Voices Drive Our Work in HS

Mar

16

UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

Mar

15

Building a Community of Trust in Epilepsy & Rare Syndromes

Feb

23

Voices on Value: Building a Sustainable Healthcare System for a Healthier Tomorrow – The Second Annual U.S. Sustainable Access and Pricing Transparency Report

Feb

17

Patient-First, Patient-Focused: Our Purpose and Promise

Feb

07

Benjamin Jessie and Kurt Hughes Use Combined 50+ Years in Industry to Create New Experiences and Forums for Colleagues

Jan

20

Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Jan

18

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact